Edgewise Therapeutics' New $175M Stock Sale Agreement and Previous Termination
Edgewise Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed
Edgewise Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15,
Edgewise Therapeutics (EWTX) Gets a Buy From RBC Capital
Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating
Edgewise Therapeutics (EWTX) has an average rating of buy and price targets ranging from $24 to $48, according to analysts polled by Capital IQ. Price: 19.52, Change: -0.48, Percent Change: -2.40
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Edgewise Therapeutics Q1 EPS $(0.33) Beats $(0.39) Estimate
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 8.33 percent increase over losses of
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator,
Edgewise Therapeutics | 10-Q: Quarterly report
Press Release: Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights -- Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND
Edgewise Therapeutics 1Q Loss/Shr 33c >EWTX
Edgewise Therapeutics 1Q Loss/Shr 33c >EWTX
Edgewise Therapeutics's EDG-7500: A Promising Contender in HCM Treatment Landscape
Edgewise Therapeutics Appoints Arlene Morris to Its Board of Directors
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arle
Edgewise Therapeutics Doses First Patient In Phase 2 CIRRUS-HCM Trial Of EDG-7500 In Obstructive Hypertrophic Cardiomyopathy
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCMtrial of EDG-7500. EDG-7500 is
Edgewise Receives EMA Orphan Drug Designations For Sevasemten For Becker And Duchenne Muscular Dystrophies
Edgewise Receives EMA Orphan Drug Designations For Sevasemten For Becker And Duchenne Muscular Dystrophies
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Royal Bank of Canada: Maintaining the Edgewise Therapeutics (EWTX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $28.00 to $32.00.
Royal Bank of Canada: Maintaining the Edgewise Therapeutics (EWTX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $28.00 to $32.00.
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $32
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $28 to $32.
Analysts Are Bullish on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Edgewise Therapeutics (EWTX)
Edgewise Therapeutics Earns 'Buy' Rating From Joseph Schwartz on Strong Clinical Data and Promising Drug Prospects
No Data